SynthesisClinical cardiology2022
Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta-analysis.
Synthesis in Clinical cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.
- Benefits of ozone on mortality in patients with COVID-19: A systematic review and meta-analysis.Complementary therapies in medicine · 2023Pooled it
- Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta-analysis.Clinical cardiology · 2022Pooled it
- Tolvaptan in heart failure: Contemporary evidence and a framework for precision decongestion.Heart failure reviews · 2026Review
- Arginine vasopressin and copeptin: comparative review and perspective in veterinary medicine.Frontiers in veterinary science · 2025Review
- Comment on: Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta-analysis.Clinical cardiology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering the prevalence of dyspnea in acute heart failure (AHF), its reduction is important to both patients and caregivers. This meta-analysis was performed to determine the efficacy and safety of tolvaptan on early dyspnea relief in patients with AHF. A systematic search was made of PubMed, Embase, Web of Science, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of AHF with tolvaptan, compared with placebo or blank, were reviewed. Studies were pooled to relative risk (RR), with 95% confidence interval (CI). Five RCTs (enrolling 4857 participants) met the inclusion criteria. Tolvaptan presented significant effects on 12 h dyspnea relief (RR: 1.98; 95% CI: 1.24-3.15; p = .004), 24 h/day 1 dyspnea relief (RR: 1.15; 95% CI: 1.07-1.24; p = .0003), 48 h dyspnea relief (RR: 1.20; 95% CI: 1.06-1.36; p = .004), and 72 h dyspnea relief (RR: 1.18; 95% CI: 1.02-1.37; p = .03). No significant increase was noticed in the incidence of worsening renal function in tolvaptan group (RR: 1.10; 95% CI: 0.87-1.39; p = .43). Tolvaptan treatment significantly improved patient-assessed dyspnea early and persistently in patients with AHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.